VisionRx provides this list of ongoing trials as a public service. If you would like us to add another study to the list, please send email to email@example.com.
Clinical Studies Currently Recruiting Patients
Note to Potential Patients: If you are interested in participating in any of the clinical studies listed below, please share this information with your eyecare professional. He or she must make contact with the clinical study researcher and provide information about your diagnosis and medical history.
STUDY: Amblyopia Treatment Trial (ATS)
Purpose: To evaluate treatments for amblyopia in children.
Currently Recruiting: Males and females 7 years old or younger with amblyopia due to strabismus or anisometropia (unequal refractive error). Visual acuity in the amblyopic eye must be between 20/50 and 20/100, visual acuity in the sound eye must be 20/40 or better, and there must be at least 3 lines of acuity difference between the two eyes. Patients must have had no more than two months of amblyopia therapy in the past two years.
Study Chair: Michael X. Repka, M.D., (410) 955-8314; e-mail: firstname.lastname@example.org.
Clinical Centers: For investigators who are currently enrolling patients, please visit the ATS website, http://public.pedig.jaeb.org/studies/ats/clinical_centers.html.
STUDY: Collaborative Longitudinal Evaluation of Ethnicity and Refractive Error (CLEERE) Study
Purpose: To study eye development in Hispanic, African American, and Asian schoolchildren as compared with Caucasian children. To investigate risk factors for the development of myopia (nearsightedness). To conduct genetic studies on nearsighted children and their families.
Currently Recruiting: Children enrolled in the first-grade in selected schools in Eutaw, Alabama; Houston, Texas; and Irvine, California, in the 1999-00 academic year.
Study Chair: Karla Zadnik, O.D., Ph.D., (614) 292-6603; e-mail: email@example.com
Clinical Centers: Alabama (Eutaw); California (Berkeley, Fullerton); Texas (Houston).
STUDY: Complications of Age-Related Macular Degeneration (CAPT)
Purpose: To determine whether use of low-intensity laser treatment in eyes with drusen in the macula can prevent later complications of age-related macular degeneration.
Currently Recruiting: Men and women, at least 50 years old, with vision in each eye of 20/40 or better. Each eye must have at least 10 large drusen and be available for follow- up examinations for 5 years after enrollment.
Study Chair: Stuart L. Fine, M.D., (215) 662-8142
Clinical Centers: Arizona (Mesa, Sun City); California (San Francisco); Florida (Miami, Tampa); Georgia (Atlanta); Iowa (Iowa City); Illinois (Chicago, Harvey); Kentucky (Louisville); Maryland (Baltimore); Massachusetts (Boston); Michigan (Royal Oak); Minnesota (Rochester); Missouri (St. Louis); New Jersey (Edison, Lakewood); North Carolina (Charlotte); Ohio (Cleveland, Columbus); Oregon (Portland); Pennsylvania (Philadelphia); Texas (Dallas); Wisconsin (Madison).
STUDY: Congenital Esotropia Observational Study (CEOS)
Purpose: To observe the early course of congenital esotropia, a form of childhood strabismus. This information will be used to determine the feasibility of conducting a clinical trial to assess the benefit of early surgery for congenital esotropia.
Currently Recruiting: Neurologically and developmentally normal infants with congenital esotropia who are between 4 and 20 weeks of age.
Study Chair: Kenneth W. Wright, M.D., (310) 855-2294; e-mail: firstname.lastname@example.org
Clinical Centers: For investigators who are currently enrolling patients, please visit the CEOS website, http://ceos.jaeb.org/investigators.html.
STUDY: Studies of Ocular Complications of AIDS (SOCA)-Ganciclovir- Cidofovir CMV Retinitis Trial (GCCRT)
Purpose: To compare the newest CMV retinitis drug, cidofovir, with a regimen of the ganciclovir intraocular device plus oral ganciclovir for preventing vision loss. To compare a treatment regimen that uses highly active local therapy (ganciclovir device) with a treatment regimen that does not.
Patient Eligibility: Males and females age 13 years and older with diagnoses of AIDS and active CMV retinitis will be eligible. Patients must have a best corrected visual acuity of > 20/100 in at least one eye affected by CMV retinitis with at least one lesion 750 µ or greater that can be photographed.
Study Chair: Douglas A. Jabs, M.D., (410) 955-1966
Clinical Centers: California (Irvine, La Jolla, Los Angeles, San Francisco); Florida (Miami, Tampa); Georgia (Atlanta); Illinois (Chicago); Indiana (Indianapolis); Louisiana (New Orleans); Maryland (Baltimore); Massachusetts (Boston); New Jersey (Newark); New York (New York); North Carolina (Chapel Hill); Texas (Houston)
STUDY: Studies of Ocular Complications of AIDS (SOCA)--Longitudinal Study of Ocular Complications of AIDS (LSOCA)
Purpose: To monitor trends in the incidence of CMV retinitis and other ocular complications of AIDS. To determine the effect of HAART-induced immune status on the risk of developing CMV retinitis and other ocular complications of AIDS. To determine the characteristics of a population at high risk for CMV retinitis and other ocular complications of AIDS. To evaluate the effects of treatments for CMV retinitis and other ocular complications on visual function, quality of life, and survival.
Patients Eligibility: Males and females age 13 years and older with diagnosis of AIDS will be eligible.
Study Chair: Douglas A. Jabs, M.D., M.S., (410) 955-1966
Clinical Centers: California (Irvine, La Jolla, Los Angeles, San Francisco); Florida (Miami, Tampa); Georgia (Atlanta); Illinois (Chicago); Indiana (Indianapolis); Louisiana (New Orleans); Maryland (Baltimore); New Jersey (Newark); New York (New York); North Carolina (Chapel Hill); Ohio (Cincinnati); Pennsylvania (Philadelphia); Texas (Galveston, Houston).
STUDY: Submacular Surgery Trials (SST)
Purpose: To determine whether surgical removal of subfoveal choroidal neovascularization (CNV) in patients with "wet" age-related macular degeneration (AMD), ocular histoplasmosis syndrome (OHS) or idiopathic CNV stabilizes or improves vision.
Currently Recruiting: Men and women with neovascular "wet" AMD.
Study Chair: Neil Bressler, M.D., (410) 502-5262;
Clinical Centers: Arizona (Phoenix); California (Los Angeles, Menlo Park, San Francisco); Georgia (Atlanta); Hawaii (Honolulu); Illinois (Chicago); Iowa (Iowa City); Kentucky (Lexington); Maryland (Baltimore); Massachusetts (Boston); Michigan (Royal Oak); Minnesota (Edina); Missouri (St. Louis); North Carolina (Durham); Ohio (Beachwood, Cleveland, Columbus, Toledo); Oklahoma (Oklahoma City); Oregon (Portland); Pennsylvania (Pittsburgh); Tennessee (Knoxville); Texas (Arlington).
Print this page
Copyright © 2005 VisionRx LLC. All Rights Reserved.